Stakeholders seek risk-based approach from FDA on regulating AI/ML for drug development
Regulatory NewsFerdous Al-Faruque
Biologics/ biosimilars/ vaccinesCombination products/companion diagnosticsDiagnostics/IVDsMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/Policy